Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …

The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid
leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease …

Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that
evolve through a multi-step process. CML is also one of the best examples of a disease that …

Targeting the tyrosine kinase activity of Bcr-Abl with STI571 is an attractive therapeutic
strategy in chronic myelogenous leukemia (CML). A few CML cell lines and primary …

Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the
Philadelphia chromosome as the sole genetic abnormality into blast crisis, which is often …

Chronic myeloid leukemia (CML) is genetically characterized by the presence of the
reciprocal translocation t (9; 22)(q34; q11), resulting in a BCR/ABL gene fusion on the …

The oncogenic BCR/ABL kinase activity induces and maintains chronic myelogenous
leukemia (CML). We show here that, in BCR/ABL-transformed cells and CML blast crisis …

Background Although the vast majority of patients with chronic myeloid leukemia (CML)
respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de …

The 2-phenylaminopyrimidine derivative STI571 has been shown to selectively inhibit the
tyrosine kinase domain of the oncogenic bcr/abl fusion protein. The activity of this inhibitor …